Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Zoom out: The positive results sent Lilly's stock soaring 16% Thursday to $852. Bank of America's Anderson projected 2030 ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, Wegovy, Mounjaro and Zepbound, a clinical trial shows.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Now, the Rocky Aur Rani Kii Prem Kahaani director has finally addressed these issues. He hosted an Instagram live session ...

Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6% and also help people lose up to 16 ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

Karan Johar came under the radar of netizens with his drastic weight transformation. The internet was left shocked when Karan ...

The former Playboy model, 39, started injecting the drug after being body-shamed by internet trolls earlier this year.

Injectable medications originally developed for the treatment of diabetes are also effective for weight loss and have surged ...